Physician profile
Reuben Valentin
NPI 1407037484
$13,846.90
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.12 · 2020: $170 · 2021: $392 · 2022: $620 · 2023: $839 · 2024: $1,330 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,820 · Food and Beverage: $3,680 · Education: $98.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,820.00 |
| Food and Beverage | $3,680.17 |
| Education | $98.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $10,330.75 | 2022-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $1,673.12 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $956.04 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $264.82 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.56 | 2023-2025 | |
| Amgen INC. | $169.66 | 2021-2025 | Krystexxa, Tavneos, Uplizna |
| Fresenius USA Marketing, INC. | $90.99 | 2022-2024 | Velphoro |
| Akebia Therapeutics INC | $67.49 | 2024 | Vafseo, Auryxia |
| Ani Pharmaceuticals, INC. | $27.84 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $24.44 | 2024 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.50 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Valentin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.